Alzamend Neuro Inc Quick Ratio (ALZN) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Alzamend Neuro Inc   (NASDAQ: ALZN)

Alzamend Neuro Inc 's Quick Ratio

ALZN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Alzamend Neuro Inc 's Cash & cash equivalent grew by 968.18 % in the Q1 2026 sequentially, faster than Current Liabilities, this led to improvement in Alzamend Neuro Inc 's Quick Ratio to 2.77, Quick Ratio remained below Alzamend Neuro Inc average.

Within Major Pharmaceutical Preparations industry 269 other companies have achieved higher Quick Ratio than Alzamend Neuro Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 755 to 832.

Explain Quick Ratio?
How much Cash & cash equivalents ALZN´s has?
What are ALZN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALZN Quick Ratio (Jul 31 2026)
Q1		 (Apr 30 2026)
Q4		 (Jan 31 2026)
Q3		 (Oct 31 2025)
Q2		 (Jul 31 2025)
Q1
Y / Y Current Liabilities Change 178.59 % 112.07 % -80.32 % -42.82 % -65.88 %
Y / Y Cash & cash equivalent Change 35.06 % -82 % 950.04 % 8.71 % 370.78 %
Quick Ratio MRQ 2.77 0.53 6.22 6.2 5.72
ALZN's Total Ranking # 832 # 755 # 814 # 790 # 4834
Seq. Current Liabilities Change 103.5 % 112.07 % -11.53 % -27.03 % 54.91 %
Seq. Cash & cash equivalent Change 968.18 % -82 % -11.25 % -20.84 % 42.35 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 270
Healthcare Sector # 464
Overall Market # 1375


Quick Ratio Statistics
High Average Low
14.56 4.2 0.05
(Jul 31 2021)   (Oct 31 2023)




Financial Statements
Alzamend Neuro Inc 's Current Liabilities $ 3 Millions Visit ALZN's Balance sheet
Alzamend Neuro Inc 's Cash & cash equivalent $ 8 Millions Visit ALZN's Balance sheet
Source of ALZN's Sales Visit ALZN's Sales by Geography


Cumulative Alzamend Neuro Inc 's Quick Ratio

ALZN's Quick Ratio for the trailling 12 Months

ALZN Quick Ratio

 (Jul 31 2026)
12 Months		 (Apr 30 2026)
12 Months		 (Jan 31 2026)
12 Months		 (Oct 31 2025)
12 Months		 (Jul 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth -10.84 % -53.96 % -71.95 % -45.65 % -51.77 %
Y / Y Cash & cash equivalent TTM Growth 18.96 % 53.25 % 197.52 % 33.24 % 103.14 %
Quick Ratio TTM 3.07 4 6.05 2.59 2.3
Total Ranking TTM # 271 # 755 # 814 # 790 # 4834
Seq. Current Liabilities TTM Growth 47.7 % 23.95 % -46.59 % -8.81 % -23.74 %
Seq. Cash & cash equivalent TTM Growth 13.38 % -18.02 % 24.82 % 2.54 % 46.06 %

Quick ratio ranking by company, industry and sector >> Back to ALZN Financial Strength Comparisons >> Go to Compare ALZN Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q1 2026 to $2.74 millions, cumulative Quick Ratio decreased to 3.07 below the Alzamend Neuro Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 478 other companies have achieved higher Quick Ratio than Alzamend Neuro Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending fourth quarter 2026 at 4366.

Explain Quick Ratio?
How much Cash & cash equivalents ALZN´s has?
What are ALZN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 479
Healthcare Sector # 972
Within the Market # 832


trailing twelve months Quick Ratio Statistics
High Average Low
6.96 5.19 3.07
(Jan 31 2023)   (Jul 31 2026)




Companies with similar Quick Ratio in the quarter ending Jul 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioJul 31 2026 MRQ Cash & cash equivalentJul 31 2026 MRQ Current Liabilities
Nuvation Bio Inc   7.62 $ 660.956  Millions$ 86.755  Millions
Ibio inc   7.50 $ 88.049  Millions$ 11.745  Millions
Promis Neurosciences inc   7.41 $ 53.463  Millions$ 7.218  Millions
Lakewood-Amedex Biotherapeutics Inc.  7.29 $ 4.585  Millions$ 0.629  Millions
Aspire Biopharma Holdings Inc   7.22 $ 12.167  Millions$ 1.686  Millions
Cartesian Therapeutics Inc   7.18 $ 147.606  Millions$ 20.550  Millions
Kiora Pharmaceuticals Inc   7.10 $ 16.839  Millions$ 2.370  Millions
Arvinas Inc   6.88 $ 567.900  Millions$ 82.500  Millions
Summit Therapeutics Inc   6.67 $ 690.749  Millions$ 103.566  Millions
Alumis inc   6.59 $ 502.300  Millions$ 76.233  Millions
Novelos Therapeutics, Inc.  6.49 $ 33.994  Millions$ 5.238  Millions
Genprex Inc   6.47 $ 15.154  Millions$ 2.342  Millions
Lisata Therapeutics Inc   6.45 $ 19.277  Millions$ 2.987  Millions
Larimar Therapeutics Inc   6.44 $ 219.880  Millions$ 34.166  Millions
United Therapeutics Corporation  6.13 $ 3,724.700  Millions$ 607.800  Millions
Serina Therapeutics Inc   6.12 $ 23.024  Millions$ 3.762  Millions
Revelation Biosciences Inc   6.11 $ 11.483  Millions$ 1.880  Millions
Spero Therapeutics Inc   6.02 $ 50.774  Millions$ 8.428  Millions
Aquestive Therapeutics Inc   5.98 $ 98.490  Millions$ 16.478  Millions
Xencor Inc  5.94 $ 486.350  Millions$ 81.865  Millions
Zymeworks Inc   5.73 $ 270.699  Millions$ 47.243  Millions
Tonix Pharmaceuticals Holding Corp   5.72 $ 176.232  Millions$ 30.785  Millions
Emmis Acquisition Corp   5.72 $ 0.708  Millions$ 0.124  Millions
Arcturus Therapeutics Holdings Inc   5.71 $ 191.483  Millions$ 33.536  Millions
Hoth Therapeutics Inc   5.70 $ 7.892  Millions$ 1.384  Millions
Silence Therapeutics Plc  5.67 $ 72.100  Millions$ 12.714  Millions
Adial Pharmaceuticals Inc   5.51 $ 28.200  Millions$ 5.121  Millions
Corbus Pharmaceuticals Holdings Inc   5.49 $ 117.941  Millions$ 21.483  Millions
Bio Green Med Solution Inc   5.48 $ 3.790  Millions$ 0.692  Millions
Arrowhead Pharmaceuticals Inc   5.47 $ 1,551.301  Millions$ 283.346  Millions

Date modified: 2026-09-18T15:21:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.